港股異動 | 中國生物製藥漲超2%,擬以5.15億美元向科興中維出資
uSMART盈立智投12月7日消息,週一港股,中國生物製藥走出了"U型"行情,截至13:54分,中國生物製藥漲2.84%,報6.88港元。
【中國生物製藥目前支持20倍槓桿日內交易】
消息面上,中國生物製藥發佈公告,附屬公司就以5.15億美元向北京科興中維生物技術有限公司出資訂立協議。
於出資完成後,公司將於科興中維的註冊資本中擁有15.03%權益。科興中維將於公司的財務報表中入賬列爲聯營公司。
公告稱,出資將爲集團帶來重要戰略夥伴,並預期雙方將共同努力,在進一步提高疫苗銷售能力、拓展海外市場及開發新技術方面加強合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.